title: [The reactogenicity of Heberbiovac-HB vaccine at different doses].
abstract: Reactogenicity was measured after applying the Heberbiovac-HB recombinant vaccine against hepatitis B virus to three groups of children aged 6-9 years. The vaccine was derived from yeast cells, administered at doses of 10, 5, and 2.5 g, with a schedule of 0, 1 and 6 months. The overall observed symptomatology was low (12.2%) in the three groups with 10.7%, 13.5%, and 12.3% for 10, 5, and 2.5 g, respectively. The predominant symptoms and signs were febricula (7.0%), local pain (3.1%), and erythema (1.2%). No significant differences were found when making a comparison between groups and sexes. An acceptable reactogenicity of the immunogen was confirmed, thus its use is recommended for the protection against hepatitis B virus.
authors.affiliation: Instituto de Medicina Tropical Pedro Kourí.
authors.forename: M
authors.initials: M
authors.lastname: Díaz González
authors.forename: O
authors.initials: O
authors.lastname: Navia Molina
authors.forename: J R
authors.initials: JR
authors.lastname: Bravo González
authors.forename: P
authors.initials: P
authors.lastname: Pedroso Flaquet
authors.forename: A
authors.initials: A
authors.lastname: Urbino López
mesh_terms: D002648:Child; D003462:Cuba; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000009:adverse effects; D004306:Dose-Response Relationship, Immunologic; D006509:Hepatitis B / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007273:Injections, Intramuscular; D013997:Time Factors; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D004274:DNA, Recombinant; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; C115360:heberbiovac-HB